Introduction
Problems in the newborn period can sometimes be predicted by biochemical measurements in late pregnancy but there is, as yet, no definitive prenatal indicator of poor fetal growth. Although modern intensive care has improved the prognosis for light weight infants, management still presents problems especially when such births are unexpected. At present, measurement of maternal serum α fetoprotein (MSAFP) between 16 and 20 weeks gestation is done primarily as a screening procedure for fetal neural tube defects (NTD). However, initial studies on the outcomes of pregnancies where high MSAFP values were found in the absence of fetal NTD suggested that these pregnancies were associated with low birth weight babies [1, 7] . Since there is no evidence that MSAFP measurement at any time other than in the second trimester might predict low birth weight infants more efficiently [2, 8] , it would be convenient if the routine MSAFP test were clinically useful in this respect. SMITH [5] has suggested that high MSAFP predicts prematurity whereas PURDIE et al. [4] concluded that growth retardation rather than prematurity was indicated. We have examined MSAFP levels in pregnancies resulting in low birth weight infants to assess their relationship in our population. Women with premature delivery and those with light for gestational age infants were analysed separately to find whether raised MSAFP was associated with one or both of these groups. Pregnancies ending in spontaneous abortion or stillbirth were also studied.
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Patients and methods
Three hundred and eighty-nine pregnancies screened for NTD in the period January 1980 to December 1981 and resulting in a liveborn singleton weighing 2.5 kg or less were included. The variables recorded for each patient were birth weight, sex and gestation at birth, and MSAFP value expressed as a multiple of the median (MOM) value according to gestation for uncomplicated pregnancies with normal outcome at term. Pregnancies which were screened over the same period and ended in spo n -taneous abortion or stillbirth were analysed separately. The MSAFP value was described as raised if it equalled or was greater than two multiples of the median value (> 2 MOM) for normal outcome in singleton pregnancies, otherwise it was classified as normal. However, for pregnancies screened in the Grampian Region of Scotland centered in Aberdeen, a MSAFP value of 2 MOM is at the 95 % centile of the normal range so that 5 % of normal outcome pregnancies will have MSAFP at or above this level. Using this information, a statistical comparison was made with the proportion of raised MSAFP levels in the samples examined, (using a normal approximation to the binomial test for comparing proportions) to investigate whether the distribution of MSAFP levels differed from the general population. Not all pregnancies resulting in low birth weight infants were screened for NTD. However, distributions of gestation, weight and sex, and whether or not the infant was light for gestational age were similar in screened and unscreened groups. Thus the screened group used in the following analysis may be assumed to be a representative sample of all low birth weight pregnancies. MSAFP was measured by double-antibody radioimmunoassay.
Results
There was no significant difference between the numbers of male and female infants. Table I shows the distribution of MSAFP levels according to birth weight. Overall there were 33 (8.5%) women with raised MSAFP levels (> 2 MOM) giving fairly strong evidence of an increased chance that women with low birth-weight babies had raised MSAFP values (p< 0/005). For birth-weights under 2.0 kg there appears to be an even greater risk: 11.7% of women had a raised MSAFP level (p< 0.001). The same may be true for those under 1.5 kg and under 1.0 kg but the sample size in these two groups is insufficient for firm conclusions to be drawn. However, there is evidence to suggest such an association (pooling MSAFP into normal/raised groups, and pooling weights < 1.5 kg, X 2 test p < 0.02). Table II shows the distribution of MSAFP according to gestational age at delivery. There is weak evidence of an association between MSAFP and gestation (X 2 test, pooling AFP groups above 2 MOM, ρ < 0.09). Although there may be an increased chance of raised MSAFP levels amongst patients delivering before 33 weeks of gestation (p < 0.02), there is very little evidence of an association between raised MSAFP and prematurity as a whole (i.e. gestation under 37 weeks). However, for low birth weight infants born after 37 weeks of gestation, there is strong evidence of an increased chance of raised MSAFP levels; in this sample 9.8% of patients who were delivered after 37 weeks had raised MSAFP values (p < 0.005). These results suggested that raised MSAFP levels might indicate intra-uterine growth retardation (IUGR), i.e. light for gestational age infants. To clarify the situation, birthweights were then compared with standard birth weight centiles [6] according to gestation, sex and parity. An infant was classified as light-for-dates if its birth weight lay below the appropriate 10th centile, otherwise it was classified as appropriate-for-dates. Sixty-four patients were not classifiable as they delivered before 32 weeks of gestation, outside the range of the available centiles. Table III shows the results of this analysis. In the light-for-dates group, 19 out of 203 (9.4%) had raised MSAFP levels, whereas in the appropriatefor-dates group, only six out of 122 (4.9%) had raised MSAFP levels, comparable with the general population. Thus there was strong evidence of an increased chance of raised MSAFP in the lightfor-dates group (p < 0.005).
Spontaneous Abortions
Fifty-five pregnancies ended in spontaneous abortion after 16 weeks where MSAFP levels had been measured prior to the abortion. Of these, eight women had raised MSAFP (14.5%). This is strong evidence (p < 0.002) that raised MSAFP occurs more frequently in pregnancies ending in spontaneous abortion than in the general population.
Stillbirths
Sixty-one pregnancies ended with a stillborn infant. Five (8.2%) women had raised MSAFP levels and there is little evidence to suggest that raised MSAFP in the second trimester has any association with subsequent stillbirth.
Discussion
These results are consistent with earlier studies, in that there appears to be an increased chance of raised MSAFP values in mothers who have infants of low birth weight. In our sample, 8.5 % of these patients had raised MSAFP levels at 16-21 weeks of gestation, compared with 13 A % at 16-20 weeks reported by SMITH [5] .
From the above analysis, high MSAFP in singleton pregnancies without fetal defect would seem to be a predictor of light-for-dates infants, and possibly also extreme prematurity. However, the apparent association between very premature infants, born at 32 weeks of gestation or less, and high MSAFP, may be due to bias: if gestation is under-estimated, this will lead to an apparently high MSAFP level, and an apparently early delivery. The association between IUGR and high MSAFP is of interest, but is unlikely to be of much practical 
